Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI

Wei Liu\textsuperscript{a}, Hatim Fakir\textsuperscript{b}, Gurpreet Randhawa\textsuperscript{c}, Ryan Alfano\textsuperscript{d}, Mark Corkum\textsuperscript{e}, Zahra Kassam\textsuperscript{f}, Irina Rachinsky\textsuperscript{g}, Hans T. Chung\textsuperscript{h,i}, Peter Chung\textsuperscript{h,i}, Andrew Loblaw\textsuperscript{h,i,k}, Gerard Morton\textsuperscript{h,i}, Tracy Sexton\textsuperscript{a}, Anil Kapoor\textsuperscript{l}, Aaron Ward\textsuperscript{m}, Katherine Zukotynski\textsuperscript{g,n}, Louise Emmett\textsuperscript{o}, Glenn Bauman\textsuperscript{a,*}

\textsuperscript{a} Department of Oncology, Division of Radiation Oncology, London Health Sciences Centre and Western University, London, Canada
\textsuperscript{b} Department of Oncology and Department of Medical Biophysics, London Health Sciences Centre and Western University, London, Canada
\textsuperscript{c} Faculty of Engineering, University of Waterloo, Waterloo, Canada
\textsuperscript{d} Department of Radiation Oncology, Windsor Regional Cancer Centre, Windsor Regional Hospital, Windsor, Canada
\textsuperscript{e} Division of Radiation Oncology, The Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, Canada
\textsuperscript{f} Department of Medical Imaging, St. Joseph’s Health Care and Western University, London, Canada
\textsuperscript{g} Division of Nuclear Medicine, London Health Sciences Centre and Western University, London, Canada
\textsuperscript{h} Departments of Radiation Oncology, Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, Canada
\textsuperscript{i} Department of Radiation Oncology, University of Toronto, Toronto, Canada
\textsuperscript{j} Department of Medical Biophysics, Lawson Health Research Institute and Western University, London, Canada
\textsuperscript{k} Institute of Health Care Policy and Evaluation, University of Toronto, Canada
\textsuperscript{l} Urologic Cancer Centre for Research & Innovation and McMaster University, Hamilton, Canada
\textsuperscript{m} Departments of Medicine and Radiology, McMaster University, Hamilton, Canada
\textsuperscript{n} Department of Nuclear Medicine and Theranostics, St. Vincent’s Hospital and University of New South Wales, Sydney, Australia

ARTICLE INFO

Keywords:
Prostate cancer
PSMA PET/CT
MRI
Radio-recurrence

ABSTRACT

Purpose: Our purpose was to evaluate intra-prostatic cancer volumes for salvage radiotherapy in men with recurrent prostate cancer confined to the prostate post-primary radiotherapy using mpMRI and 18F-DCFPyL PET/CT (PET).

Methods: Men with biochemical failure post-primary radiotherapy were enrolled in a multi-centre trial investigating mpMRI and PET. All men with isolated intra-prostatic recurrence are included in this secondary analysis. The intra-prostatic gross tumour volume (GTV) was manually delineated on mpMRI and was also delineated on PET using three methods: 1. manually, 2. using a 30% threshold of maximum intra-prostatic standard uptake value (SUVmax), and 3. using a 67% threshold of this SUVmax. Clinical target volumes (CTV) including expansions on each GTV were generated. Conformity indices were performed between the mpMRI CTV and each PET CTV. Correlation with biopsy and clinical outcomes were performed.

Results: Of the 36 men included, 30 (83%) had disease in two quadrants or less using the combination of mpMRI and PET. Mean target volume (union of CTV on mpMRI and CTV manually delineated on PET) was 12.2 cc (49% of prostate gland volume). 12/36 (33%) men had a biopsy. Per-patient sensitivity was 91% for mpMRI and 82% for PET.

Conclusions: mpMRI and PET provide complementary information for delineation of intra-prostatic recurrent disease. Union of CTV on mpMRI and PET is often less than 50% of the prostate, suggesting this imaging could help define a target for focal salvage therapy.

* Corresponding author at: London Health Sciences Centre, 800 Commissioners Rd E, London, ON N6A 5W9, Canada.
E-mail address: Glenn.Bauman@lhsc.on.ca (G. Bauman).

https://doi.org/10.1016/j.ctro.2021.11.006
Received 13 September 2021; Received in revised form 8 November 2021; Accepted 8 November 2021
Available online 14 November 2021
2405-6308/© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction:

Up to 35% of prostate cancer patients treated with dose-escalated external beam radiotherapy (EBRT) experience biochemical failure (BF) by Phoenix Criteria [1] within 10 years [2]. Local salvage treatment such as radical prostatectomy, brachytherapy, cryoablation, high-intensity focused ultrasound (HIFU), and stereotactic body radiotherapy (SBRT) provide durable biochemical control in only half of these patients and are associated with severe genitourinary or gastrointestinal toxicity in up to 25% of cases [3]. As a consequence, local salvage treatment is infrequently used, and most patients with recurrent disease are given androgen deprivation therapy (ADT) or are placed under observation [4–5]. Next generation imaging techniques may improve local salvage therapy outcome through more precise intra-prostatic recurrence targeting (potentially lowering toxicity) and early identification of men with metastatic disease (potentially enabling better patient selection for long-term control) [6–7].

Focal salvage therapy that targets only part of the prostate gland has been investigated, with the goal of decreasing toxicity compared to whole-gland re-irradiation [8]. Until recently, multi-parametric magnetic resonance imaging (mpMRI) has been the preferred imaging modality for target delineation, but may miss small lesions and underestimate disease volume in both the primary and post-radiotherapy settings [9–11]. Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) may improve focal salvage outcome through improved intra-prostatic target delineation with the added benefit of improved patient selection (by excluding men with distant disease). A prospective, single-arm study showed PSMA-targeted PET/CT detected extra-prostatic disease in more patients with BF after primary radiotherapy compared to conventional imaging [12]. Also, prior to primary prostatectomy, the combination of PSMA-targeted PET/CT and mpMRI has increased sensitivity for the detection of intra-prostatic disease compared to either technique alone, suggesting a role for target delineation [13–14]. To our knowledge, no study to date has evaluated the combination of PSMA-targeted PET/CT and mpMRI for target volume delineation in men with locally recurrent prostate cancer after radiotherapy.

Methods

PICS (NCT02793284) is a multi-center prospective trial of 79 men with BF after primary EBRT or brachytherapy for localized prostate cancer [12]. Ethics approval was obtained from the Ontario Cancer Research Ethics Board and all patients signed informed consent. Eligibility criteria included localized T1-2 prostate cancer with zero or one high-risk feature (prostate-specific antigen [PSA] greater than 20 ng/mL or Gleason Grade 8) treated with primary radiotherapy to conventional imaging [12]. Also, prior to primary prostatectomy, the combination of PSMA-targeted PET/CT and mpMRI has increased sensitivity for the detection of intra-prostatic disease compared to either technique alone, suggesting a role for target delineation [13–14]. To our knowledge, no study to date has evaluated the combination of PSMA-targeted PET/CT and mpMRI for target volume delineation in men with locally recurrent prostate cancer after radiotherapy.

We also explored PET/CT volumes using a threshold of the maximum SUV (SUVmax). Volumes generated using a 20% threshold of the maximum intra-prostatic SUV were too large for focal therapy and were dismissed. We produced the GTV PET 30% using a 30% threshold of the intra-prostatic disease SUVmax. No margin was added for the CTV PET 30% as there is good concordance in the primary setting with histologic volumes [19]. The GTV PET 67% was generated using a 67% threshold of the intra-prostatic disease SUVmax. The GTV PET 67% was modified to exclude discreet regions of SUV spillage from the bladder into the prostate. An 8.5 mm expansion limited to the prostate gland was included for CTV PET 67%. This method has been shown to have sensitivity and specificity of 95% and 76% respectively based on whole-mount histopathology in the primary prostatectomy setting [16]. Union volumes of the CTV MRI and each CTV PET were generated. All target volumes were compared.

Involvement by quadrant was based on the GTV MRI, GTV PET Manual, or union of both volumes. Dice similarity coefficient (DICE), Hausdorff distance (HD), mean distance to agreement (MDA), and Jaccard index were performed for the CTV MRI and each CTV PET. Single factor analysis of variance and post-hoc Tukey test were performed between CTV comparisons for each of the DICE, HD, MDA and Jaccard index.

Clinical management was prospectively captured as part of the PICS clinical trial. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated where post-PET/CT biopsy information was available. We also report oncologic...
outcomes for patients from this cohort who were treated with focal salvage brachytherapy.

Results

40/79 men (51%) had isolated intra-prostatic recurrence. Forty-two men had isolated intra-prostatic recurrence on mpMRI and 38 on PET/CT. 10/42 men with isolated intra-prostatic recurrence on mpMRI had extraprostatic disease on PET/CT and were excluded. None of the 38 men with isolated intra-prostatic recurrence on PET/CT had extraprostatic disease on mpMRI. Four men either did not have accessible mpMRI or had an endorectal coil for the mpMRI and were excluded. Of the 36 men included in this study, isolated recurrence was detected on mpMRI alone (n = 2), PET/CT alone (n = 6), or mpMRI and PET/CT (n = 28). Patient characteristics are shown in Table 1. The median PSA at enrolment was 4.7 ng/mL (range 2.1–65.1) and median PSA doubling time (PSADT) was 14.5 months (range 1.9 to 48.6 months). PET/CT was performed a median of 10 days after the mpMRI.

Involvement by prostate gland quadrant is shown in Fig. 2. 30/36 men (83%, 95% confidence interval 68–92%) had involvement of two quadrants or less. 28/36 (78%) men had at least one lesion detected on mpMRI or had an endorectal coil for the mpMRI and were excluded. Of the 36 men included in this study, isolated recurrence was detected on mpMRI alone (n = 2), PET/CT alone (n = 6), or mpMRI and PET/CT (n = 28). Patient characteristics are shown in Table 1. The median PSA at enrolment was 4.7 ng/mL (range 2.1–65.1) and median PSA doubling time (PSADT) was 14.5 months (range 1.9 to 48.6 months). PET/CT was performed a median of 10 days after the mpMRI.

Table 1
Baseline patient characteristics.

| Characteristic                  | Statistic          | Result          |
|--------------------------------|--------------------|-----------------|
| N                              | 36                 |                 |
| Age (Mean (std dev))           | 74.8 (7.9)         |                 |
| Median (range)                 | 76 (55, 88)        |                 |
| Initial T Stage N (%)          |                    |                 |
| T1                             | 25 (69)            |                 |
| T2                             | 1 (3)              |                 |
| T2a                            | 6 (17)             |                 |
| T2b                            | 3 (8)              |                 |
| T2c                            | 1 (3)              |                 |
| Initial Gleason Score N (%)    |                    |                 |
| 3                              | 13 (36)            |                 |
| 4                              | 15 (42)            |                 |
| 4 + 3                          | 8 (22)             |                 |
| Initial PSA (Mean (std dev))   | 9.5 (11.0)         |                 |
| Median (range)                 | 7.4 (1.8–71.0)     |                 |
| Initial NCCN risk group N (%)  |                    |                 |
| Low risk                       | 11 (31)            |                 |
| Intermediate risk              | 24 (67)            |                 |
| High risk                      | 1 (3)              |                 |
| PSA at enrolment               |                    |                 |
| Mean (std dev)                 | 8.2 (10.6)         |                 |
| Median (range)                 | 4.7 (2.1–65.1)     |                 |
| PSA Doubling Time, MSKCC (months) | 17.3 (10.6) |                 |
| Median (range)                 | 14.5 (1.0, 48.6)   |                 |
| Previous Radiotherapy N (%)    |                    |                 |
| EBRT                           | 22 (61)            |                 |
| Brachytherapy                  | 14 (39)            |                 |

Discussion

Most patients with recurrent prostate cancer after primary radiotherapy are either observed or are given palliative ADT; rarely is salvage therapy offered [4–5]. Concerns regarding treatment-related toxicity and identification of localized recurrence likely contribute to underutilization of salvage treatment. A meta-analysis of salvage therapies reported a pooled severe GU toxicity rate of 21% for salvage prostatectomy with slightly lower rates for SBRT or brachytherapy [3]. In a prospective study of whole-gland salvage low dose-rate brachytherapy (sLDR), 14% of patients had late grade 3 toxicity [21]. Focal salvage, which spares a portion of the prostate, may be associated with less toxicity; however, an optimal strategy for target delineation has not been established. Often mpMRI is used to guide focal salvage [22–25], but in salvage prostatectomy studies, mpMRI was found to underestimate the true volume of disease recurrence [9–10].

We found that the union of GTV MRI and GTV PET Manual included two quadrants or less of the prostate gland in the majority of men (83%) with isolated intra-prostatic radio-recurrent disease, suggesting a role for targeted salvage therapy. We delineated the target disease using both mpMRI and PET/CT with methods that have been histologically validated in the primary treatment setting. Gibson et al. showed that an 8 mm expansion of a mpMRI-delineated GTV was required to achieve 95%...
median sensitivity and that this spared 47–72% of the prostate gland [15]. Alfano et al. showed that an 8.4 mm expansion of a PSMA-targeted PET/CT-delineated GTV using a 67% threshold of intra-prostatic SUVmax achieved 95% mean sensitivity and spared 63% of the prostate gland [16]. Zamboglou et al. showed that using manual delineation for the GTV on PET/CT achieved a median sensitivity and specificity of 86–89% and 73–92% respectively, while using semi-automatic contours with a 30% threshold of intra-prostatic SUVmax achieved median sensitivity and specificity of 83% and 90% respectively [17].

PET/CT and mpMRI appear to be complementary for detecting...
detecting recurrence prior to focal salvage therapy. Combined PET/CT and mpMRI compared to either modality alone, we agreement. CTV PET Manual had better agreement with CTV MRI than 11%. Based on the improved but still imperfect sensitivity and NPV of with combined PET/CT and mpMRI, the false negative rate per-lobe was has been shown that both mpMRI and PSMA-targeted PET/CT poten\-tially miss radio-recurrent lesions. Dinis Fernandes et al. showed that patients may have had undetected metastatic disease at time of salvage \-clusion criteria, the 10-year BF rate after whole-gland sLDR was 46%, compared to the 10-year local failure rate of 5%, suggesting many pa-\-tients. We did, however, find excellent concordance when confirmatory biopsy results were available [26]. Our study, even with combined PET/CT and mpMRI, the false negative rate per-lobe was 11%. Based on the improved but still imperfect sensitivity and NPV of combined PET/CT and mpMRI compared to either modality alone, we recommend biopsy in addition to co-registered PET and mpMRI for detecting recurrence prior to focal salvage therapy. The optimal method for delineation of locally radio-recurrent prostate cancer based on PET and mpMRI is not known. We explored agreement between volumes using several metrics. DICE and Jaccard indices are overlap metrics, with range 0 to 1 [27–28]. HA is the maximum distance between two surfaces and MDA is the mean distance between two surfaces, with smaller distances representing better surface agreement. CTV PET Manual had better agreement with CTV MRI than CTV PET 30% according to the DICE, HD, MDA and Jaccard index. These metrics also showed that the CTV PET Manual trended towards better agreement with CTV MRI compared to CTV PET 67%. This suggests the union of CTV MRI and CTV PET Manual should be further investigated as a method for target delineation for focal salvage, either with comparison to salvage prostatectomy histopathology or with prospective clinical trials. The ultimate success of local salvage therapy depends on identification of men with localized intra-prostatic recurrence; however, identification of these patients has been challenging using conventional imaging. In RTOG-0526, trialists aimed to select patients with a high likelihood of localized recurrence. Inclusion criteria included biopsy-proven local recurrence, BF at least 30 months after EBRT, initial low or intermediate-risk disease, pre-salvage PSA of 10 or less, and negative restaging BS and CT abdomen/ pelvis [21]. However, despite these inclusion criteria, the 10-year BF rate after whole-gland sLDR was 46%, compared to the 10-year local failure rate of 5%, suggesting many patients may have had undetected metastatic disease at time of salvage [29]. PSMA PET/CT improves selection of patients for salvage therapy. In PICS, we found that PSMA PET/CT detected extra-prostatic disease in twice as many patients (39% vs. 19%) compared to the combination of bone scan; CT of the chest, abdomen and pelvis; and mpMRI of the pelvis [12]. It is not currently known if improved patient selection with PSMA-targeted PET/CT also improves oncologic outcomes for patients with local radio-recurrence who undergo salvage therapy. Encouragingly, the EMPIRE-1 randomized trial showed improved 3-year event-free survival in men with BF after prostatectomy who received PET-directed salvage treatment compared to salvage treatment based on conventional imaging [30]. Similar to our results after sHDR, van Son et al. reported biochemical disease-free survival of 51% at a median follow-up of 31 months in 50 locally radio-recurrent patients who underwent ultra-focal SHDR to a dose of 19 Gy in one fraction [18]. GTV was delineated using mpMRI and PET was used to confirm the location. A 5mm CTV margin was used. 22/26 patients with second BF had intra-prostatic recurrence. The authors suggested the high local recurrence rate may be secondary to the target volumes and dose fractionation. They discussed that a 5 mm margin to MRI-derived GTV may not be sufficient. In another study, 25 men with isolated local radio-recurrent disease and concordant mpMRI and PSMA-targeted PET/CT findings underwent focal salvage SBRT [31]. Freedom from BF was 80% at 2 years. Ultimately, randomized studies evaluating oncologic outcomes after salvage therapy for patients with radio-recurrent prostate cancer are needed. Our study has limitations. Pathologic confirmation of the mpMRI and PSMA targeted PET/CT-derived volumes was not available for all patients. We did, however, find excellent concordance when confirmatory biopsies were available (11/36 men). Further, our analysis included mostly patients with initial low or intermediate risk prostate cancer (97%), PSA less than 10 prior to imaging (89%), and PSADT of more than 6 months (89%). As such, these results may not apply to other populations. The strengths of this study include the novel analysis of radio-recurrent intra-prostatic volumes using both PSMA-targeted PET/CT and mpMRI; image acquisition through a prospective, multi-center clinical trial; and correlation with biopsy results. Conclusions mpMRI and PSMA-targeted PET/CT provide complementary information for delineation of intra-prostatic recurrent disease. Union of CTV on MRI and PET included less than 50% of the gland in most men, suggesting use of this imaging could help define focal salvage therapy. Financial disclosures Dr. Peter Chung reports other from Sanofi, personal fees from Abb-\-Vie, other from Tersera, personal fees from Astra Zeneca, personal fees from Boston Scientific, personal fees from Verity, outside the submitted work. Dr. Glenn Bauman reports grants from Ontario Institute for Cancer Research and a CARO ACURA grant, during the conduct of the study. Dr. Katherine Zukotynski reports grants from Ontario Institute for Cancer Research, Prostate Cancer Canada and the Canadian Cancer Society, during the conduct of the study.

Table 2

| CTV PET | 0.70 | 0.65-0.75 | 0.53 | 0.47-0.59 | 0.75 | 0.69-0.81 |
| CTV MRI | 11.9 | 9.5-14.4 | 15.1 | 12.8-17.4 | 8.3 | 6.0-10.6 |
| CTV PET | 2.3 | 1.7-2.9 | 3.7 | 2.9-4.5 | 1.6 | 1.0-2.3 |
| CTV MRI | 0.57 | 0.51-0.63 | 0.39 | 0.32-0.45 | 0.64 | 0.57-0.71 |

| CTV PET Manual | 0.59 | 0.47-0.65 |
| CTV MRI | 0.75 | 0.65-0.81 |

Table 3

| NCCN Risk Group | Previous radiation | Pre-salvage PSA | PSA Doubling time (months) | Dose | Fractions | Follow-up (months) | Local failure | Biochemical failure |
|-----------------|--------------------|-----------------|-----------------------------|------|-----------|-------------------|--------------|-------------------|
| Low Brachytherapy | 2.8                | 4.5             | 27 Gy 2                    | 32.1 | no        | yes               |
| Intermediate | EBRT | 3.2 | 13.5 | 27 Gy 2 | 31.0 | no | no |
| Low Brachytherapy | 3.4                | 36.4            | 27 Gy 2                    | 34.5 | no        | no                |
| Low Brachytherapy | 3.4                | 7               | 27 Gy 2                    | 31.4 | yes       | yes               |
Support
This study was funded by grants from the Ontario Institute for Cancer Research (OICR #CTI-PIcs-LHR) and the Canadian Association of Radiation Oncology.

Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References
[1] Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GI, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65(4): 965-74. https://doi.org/10.1016/j.ijrobp.2006.04.029.
[2] Oh J, Tyldesley S, Pai HH, McKenzie MR, Halperin RM, Duncan GG, et al. An updated analysis of survival endpoints for ASCENDE-RT, a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2020;108(3):562. https://doi.org/10.1016/j.ijrobp.2020.07.2194.
[3] Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol 2020;38(17):1963–70. https://doi.org/10.1200/JCO.20.01856.
[4] Dinis Fernandes C, Ghobadi G, van der Poel HG, de Jong J, Heijmink SWTPJ, et al. Quantitative 3-T multi-parametric MRI and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2016;96(1):188–96. https://doi.org/10.1016/j.ijrobp.2016.04.018.
[5] Affano R, Bauman GS, Liu W, Thiessen JD, Rachinsky I, Pavlosky W, et al. Histologic validation of auto-contoured dominant intraprostatic lesions on [18F]DCFPyl PET/CT imaging. Radiother Oncol 2020;152:53–41. https://doi.org/10.1016/j.ijrobp.2020.07.008.
[6] Zamboglou C, Fassbender TF, Steffan I, et al. Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiother Oncol 2019. https://doi.org/10.1016/j.ijrobp.2019.07.002. Published online August 17.
[7] van Son MJ, Peters M, Moerland MA, Ladokhin AJJW, Eppinga WSC, Shah TT, et al. MRI-guided ultrafocal salvage high-dose-rate brachytherapy for localized radio-recurrent prostate cancer: updated results of 50 patients. Int J Radiat Oncol Biol Phys 2020;107(1):126–35. https://doi.org/10.1016/j.ijrobp.2020.01.023.
[8] Khoo CC, Miah S, Connor MJ, Tam J, Winkler M, Ahmed HU, et al. A systematic review and meta-analysis of local salvage therapies after radiographic failure following radical prostatectomy or radiation therapy: An analysis from the CAPSURE registry. Cancer 2014;120(4):507–12. https://doi.org/10.1002/cncr.28446.
[9] Tran H, Kwok J, Pickles T, Tyldesley S, Black PC. Underutilization of local salvage after radiation therapy for prostate cancer after the work reported in this paper. Clinical and Translational Radiation Oncology 32 (2022) 41–47.